3. Out with the old, in with the new?

J&J got a thumbs down from a US district court regarding a patent on its blockbuster drug, Remicade, opening the door for biosimilar entries to the US market. Celltrion and Pfizer’s Hospira have their infliximab biosimilar, Inflectra, ready and raring to go for a launch as early as October 3. The biosimilar is already available in Europe and has been stealing a significant chunk of Remicade sales. However, J&J is planning to appeal the court’s ruling and considers a biosimilar launch prior to the outcome of the appeal to be an “at-risk launch.” Whether Celltrion and Pfizer will take that risk remains to be seen. Also TBD is how formularies will treat the products post-biosimilar entry. Will Remicade be blacklisted in favor of its sure-to-be-cheaper twin?